Medicus Pharma Ltd. Stock

Equities

MDCX

CA58471K1030

Pharmaceuticals

Market Closed - Toronto S.E. 11:29:03 2024-05-31 am EDT 5-day change 1st Jan Change
1.99 CAD -0.50% Intraday chart for Medicus Pharma Ltd. +2.05% -0.50%
Sales 2023 * - Sales 2024 * - Capitalization 32.15M 23.57M
Net income 2023 * - Net income 2024 * - EV / Sales 2023 * -
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * -
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 52.65%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.50%
1 week+2.05%
1 month-11.56%
3 months-17.43%
6 months-28.93%
Current year-0.50%
More quotes
1 week
1.85
Extreme 1.85
2.01
1 month
1.84
Extreme 1.84
2.20
Current year
1.84
Extreme 1.84
3.00
1 year
0.31
Extreme 0.31
3.05
3 years
0.31
Extreme 0.31
3.05
5 years
0.31
Extreme 0.31
3.05
10 years
0.31
Extreme 0.31
3.05
More quotes
Date Price Change Volume
24-05-31 1.99 -0.50% 300
24-05-30 2 -.--% 4,100
24-05-29 2 -0.50% 1,000
24-05-27 2.01 +3.08% 300
24-05-24 1.95 -2.50% 3,200

Delayed Quote Toronto S.E., May 31, 2024 at 11:29 am EDT

More quotes
Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company focused on investing in novel life sciences and bio-technology companies through Food and Drug Administration (FDA) approved clinical trials. The Company identifies, acquires and advances relatively de-risked clinical stage assets through clinical development and commercialization. The Company is exploring to expand its drug development pipeline through acquisitions and partnerships. The Company, through its subsidiary, SkinJect, Inc., is focused on the development of a drug delivery system using novel dissolvable microneedle arrays for the treatment of certain skin cancers. SkinJect is a novel, minimally invasive treatment for common forms of non-melanoma skin cancer, basal cell and squamous cell carcinoma.
Calendar
More about the company

Chiffre d''affaires - Rate of surprise